Recursion Pharmaceuticals Raises $200M

AI-driven drug discovery company using high-throughput biology and machine learning to find new treatments for diseases

Key Highlights

Funding Amount: $200M
Valuation: $3.5B
Headquarters: Salt Lake City, UT
Founded: 2013
Employees: 300-500
Total Raised: $676M

About the Funding Round

Recursion Pharmaceuticals has successfully closed $200M in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

Baillie Gifford
ARCH Venture Partners
Mubadala

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Recursion Pharmaceuticals achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Recursion Pharmaceuticals's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2013 and headquartered in Salt Lake City, UT, Recursion Pharmaceuticals has established itself as an innovative player in the biotech space. With 300-500 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Recursion Pharmaceuticals plans to:

Accelerate product development and innovation
Expand into new markets and geographies
Grow the team across engineering, sales, and operations
Strengthen partnerships with key industry players
Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Recursion Pharmaceuticals's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.

For more information about Recursion Pharmaceuticals, visit their website or contact their press office.

Recursion Pharmaceuticals